Induced pluripotent stem cells as suitable sensors for fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome.
Monzón-Nomdedeu, María B, Morten, Karl J, Oltra, Elisa · World journal of stem cells · 2021 · DOI
Quick Summary
This review examines whether special laboratory cells called induced pluripotent stem cells (iPSCs) could be used as 'sensors' to detect ME/CFS and fibromyalgia. The researchers found that patients with these conditions have unusual chemicals in their blood and body fluids that differ from healthy people. They propose that iPSCs could be grown in patient samples to detect these abnormal chemicals, potentially helping diagnose these diseases and predict how patients might respond to future treatments.
Why It Matters
Current ME/CFS and fibromyalgia diagnosis relies on symptom assessment without specific biomarkers, leading to diagnostic delays and uncertainty. If iPSCs can reliably detect disease-associated plasma factors, this could enable objective diagnostic testing and personalized medicine approaches. This work may eventually help identify which patients benefit from particular treatments, improving clinical outcomes.
Observed Findings
Eighteen previous metabolomic studies document commonly altered metabolites in ME/CFS and fibromyalgia body fluids
Patient plasma/serum factors can alter iPSC morphology, differentiation state, and growth patterns in laboratory settings
Multiple anomalies are consistently found in blood and plasma of FM and ME/CFS patients compared to healthy controls
In vitro cell-based assays show potential as screening platforms for detecting disease-associated factors
Inferred Conclusions
iPSCs demonstrate high sensitivity to environmental cues and could function as robust, reproducible reporters of metabolic disease states
The existence of metabolic imbalances in ME/CFS and fibromyalgia can be evidenced through iPSC-based screening platforms
Culturing iPSCs in patient-conditioned medium may predict individual treatment responses and support precision medicine approaches
Remaining Questions
Can iPSC-based screening accurately distinguish ME/CFS from fibromyalgia and other conditions with overlapping symptoms?
What are the specific molecular mechanisms by which patient plasma factors alter iPSC behavior, and do these mechanisms relate to disease pathogenesis?
Will iPSC screening prove cost-effective and practical for routine clinical diagnostic use compared to current assessment methods?
What This Study Does Not Prove
This review does not prove that iPSCs can actually diagnose ME/CFS or fibromyalgia in clinical practice—it proposes a hypothesis based on existing metabolic data. The study cannot establish causation between detected plasma factors and disease mechanisms, only that correlations exist. No prospective validation studies or clinical applications are demonstrated.